ew tavr keep prove skeptic
wrong strong guidanc higher
tavr grew includ us describ in-lin
market suggest tavr ew posit market remain
healthi tavr guidanc rais high end
good trend better fxoveral guidanc also taken higher mitral
updat also encourag pascal set enter market
come stay buy
tavr remain healthi underli us sale grew global sale
also market dynam seem stabl ew note grew in-lin market
us ou price also unchang guidanc tavr rais
upper end rangehalf better fx half market
new competit ew launch new product includ centera ultra
year eu grow awar outlook remain good
overal outlook rais comfort upper-end tavr
midpoint surgic critic along better fx revenu
guidanc rais upper-end previou guidanc one notabl
place upsid surgic ew post growth valv
benefit expand reimbursementthi like continu better
top-lin lower tax wide rang result still work
tax law ep expect
goe
mitral get real mitral tricuspid rapidli come focu big
opportun ew gener new therapi
expect add least point growth near-term opportun
pascal expect receiv ce mark pascal enter market
abt mitraclip alreadi sale ew take good amount
share expect cardioband mitral tricuspid also slowli gain traction
stori wellmuch still come transcathet aortic market
prove larger previous thought develop faster even aggress
assumpt buy rate remain believ tavr market continu outpac
expect mitral becom larger part stori
pt ep in-lin growth peer risk includ competit clinic
timelin price
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
edward tavr market leader develop
key driver growth valuat us market
develop remain key area focu
progress mitral continu could substanti
anticip strong adopt tavr ew sapien
valv next sever year base posit clinic
data technolog advanc
rate extent tavr adopt within variou
risk strata higher risk categori remain key
variabl inform addit clinic studi
registri
pt repres ep in-lin growth
mitral could substanti expand address market
peer risk includ pipelin setback competit
transcathet valv
signific expans patient popul
upsid market share forecast new technolog
label expans
earlier commerci rapid market
develop mitral
upsid tavr market growth share assumpt
faster tmvr market develop assum dcf would
suggest share price rang
slower adopt tavr lower risk patient segment
flatten penetr us and/or price declin
inroad competitor tavr program lower ew
delays/setback mitral
conserv assumpt dcf model point
clinic regulatori commerci develop
edward competitor tavr program
progress penetr global tavr market
progress mitral pipelin program
page
pleas see import disclosur inform page report
page
pleas see import disclosur inform page report
edward lifesciencesincom statement million except per share amount fye dec total growth sale gross ensestot oper oper oper expens inc incom incom tax ens incom growth dilut
page
pleas see import disclosur inform page report
